Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy

Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy

Summary: The goal of therapeutic cancer vaccines and immune checkpoint therapy (ICT) is to promote T cells with anti-tumor capabilities. Here, we compared mutant neoantigen (neoAg) peptide-based vaccines with ICT in preclinical models. NeoAg vaccines induce the most robust expansion of proliferating...

Full description

Bibliographic Details
Main Authors: Sunita Keshari, Alexander S. Shavkunov, Qi Miao, Akata Saha, Tomoyuki Minowa, Martina Molgora, Charmelle D. Williams, Mehdi Chaib, Anna M. Highsmith, Josué E. Pineda, Sayan Alekseev, Elise Alspach, Kenneth H. Hu, Marco Colonna, Kristen E. Pauken, Ken Chen, Matthew M. Gubin
Format: Article
Language:English
Published: Elsevier 2024-11-01
Series:Cell Reports
Subjects:
CP: Immunology
CP: Cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124724012269

Internet

http://www.sciencedirect.com/science/article/pii/S2211124724012269

Similar Items